Evidence mapPaperPMID 41001676Full record

ReviewFrontiers in endocrinology2025

Type 2 diabetes mediated heart failure: focus on early recognition and clinical strategies.

Xi Chen, Wei Li, Junwei Zheng, Meinv Huang, Jinxi Wang, Meifang Wu

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xi ChenDepartment of Cardiology, Affiliated Hospital of Putian University, Putian, Fujian, China.
Wei LiDepartment of Cardiology, Affiliated Hospital of Putian University, Putian, Fujian, China.
Junwei ZhengDepartment of Cardiology, Affiliated Hospital of Putian University, Putian, Fujian, China.
Meinv HuangDepartment of Cardiology, Affiliated Hospital of Putian University, Putian, Fujian, China.
Jinxi WangDepartment of Cardiology, Affiliated Hospital of Putian University, Putian, Fujian, China.
Meifang WuDepartment of Cardiology, Affiliated Hospital of Putian University, Putian, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) is an important risk factor for the development of heart failure (HF), both directly by impairing cardiac function and indirectly through related conditions such as hypertension, coronary heart disease, renal dysfunction, and other metabolic disorders. The prevention of T2DM-related HF is a comprehensive management process involving complex and multifactorial pathogenic mechanisms. An in-depth exploration of the pathophysiological and clinical risk factors of HF in T2DM can assist clinicians in identifying individuals at high risk of HF, enabling early intervention measures to prevent its onset. In this review, we present data on the pathophysiology and epidemiology of T2DM-mediated HF, clinical phenotypic features of cardiomyopathy, and summarize clinical risk factors predicting HF development identified in multiple studies, risk assessment tools, and clinical trial data on the efficacy of lifestyle modifications, pharmacological treatments, and bariatric surgical interventions. Finally, we discuss best practice recommendations for clinicians, highlight potential limitations and challenges, and propose possible future research directions.

Indexed as

Diabetes Mellitus, Type 2Diabetic CardiomyopathiesHeart FailureEarly DiagnosisHumansRisk Factorsdiabetic cardiomyopathyheart failurepreventionrisk stratificationtype 2 diabetes mellitus

Identifiers

PMID41001676
PMCPMC12457163

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.